Key terms
About BSX
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BSX news
Today
4:47am ET
Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)
Yesterday
1:20pm ET
Upcoming Deadline to Share in Boston Scientific Corporation (BSX) Class Action Settlement
Yesterday
7:10am ET
Boston Scientific (BSX) Receives a Buy from Truist Financial
Yesterday
6:59am ET
Boston Scientific price target raised to $83 from $81 at Canaccord
Yesterday
6:55am ET
Boston Scientific (BSX) Gets a Buy from RBC Capital
Yesterday
6:47am ET
Boston Scientific price target raised to $85 from $79 at Citi
Yesterday
6:37am ET
Boston Scientific price target raised to $85 from $80 at Mizuho
Yesterday
6:29am ET
Boston Scientific price target raised to $84 from $79 at Baird
Yesterday
6:22am ET
Boston Scientific price target raised to $82 from $72 at Wells Fargo
Yesterday
5:43am ET
Boston Scientific: Strong Q1 Performance and Promising Future Drive Buy Rating
Yesterday
5:40am ET
Boston Scientific (BSX) Poised for Growth: A Buy Recommendation Amid Strong Q1 Performance and Strategic Acquisitions
Apr 24
4:30pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and CureVac (CVAC)
Apr 24
4:20pm ET
Boston Scientific price target raised to $73 from $63 at Deutsche Bank
Apr 24
4:15pm ET
Boston Scientific: Strong Q1 Performance and Raised Forecasts Bolster Buy Rating
Apr 24
2:05pm ET
Buy Rating for Boston Scientific: Strong Q1 Performance and Promising Cardiology Pipeline Fuel Optimism
Apr 24
1:53pm ET
Boston Scientific price target raised to $83 from $70 at Stifel
Apr 24
9:10am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Boston Scientific (BSX) and Biogen (BIIB)
Apr 24
7:03am ET
Boston Scientific sees FY24 adjusted EPS $2.29-$2.34, consensus $2.25
Apr 24
7:01am ET
Boston Scientific sees Q2 adjusted EPS 57c-59c, consensus 56c
Apr 24
7:00am ET
Boston Scientific reports Q1 adjusted EPS 56c, consensus 51c
Apr 23
8:25pm ET
Notable companies reporting before tomorrow’s open
Apr 23
1:18pm ET
Notable companies reporting before tomorrow’s open
Apr 22
7:56am ET
Stryker added to ‘Tactical Outperform’ list at Evercore ISI
Apr 17
2:32pm ET
Boston Scientific recalls 1,594 Obsidio Embolic devices in U.S.
Apr 15
8:06am ET
Boston Scientific price target raised to $78 from $70 at RBC Capital
Apr 15
7:35am ET
Boston Scientific price target raised to $74 from $72 at BTIG
Apr 15
6:08am ET
Integer upgraded to Buy from Neutral at BofA
Apr 05
12:15am ET
Evercore ISI Keeps Their Buy Rating on Boston Scientific (BSX)
Apr 03
11:51am ET
Boston Scientific price target raised to $80 from $69 at Argus
Apr 03
5:51am ET
Boston Scientific price target raised to $79 from $71 at Citi
Mar 27
8:14am ET
Piper says competitive process could materialize for ShockWave
No recent press releases are available for BSX
BSX Financials
Key terms
Ad Feedback
BSX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BSX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
